|
1
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Angelico G, Mazzucchelli M, Attanasio G,
Tinnirello G, Farina J, Zanelli M, Palicelli A, Bisagni A,
Barbagallo GMV, Certo F, et al: H3K27me3 loss in central nervous
system tumors: Diagnostic, prognostic, and therapeutic
implications. Cancers (Basel). 16:34512024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McNamara C, Mankad K, Thust S, Dixon L,
Limback-Stanic C, D'Arco F, Jacques TS and Löbel U: 2021 WHO
classification of tumours of the central nervous system: A review
for the neuroradiologist. Neuroradiology. 64:1919–1950. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cabrera AR, Kirkpatrick JP, Fiveash JB,
Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M,
et al: Radiation therapy for glioblastoma: Executive summary of an
American society for radiation oncology evidence-based clinical
practice guideline. Pract Radiat Oncol. 6:217–225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen PY, van den Bent M, Youssef G,
Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de
Groot J, Gilbert MR, et al: RANO 2.0: Update to the response
assessment in neuro-oncology criteria for high- and low-grade
gliomas in adults. J Clin Oncol. 41:5187–5199. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwartzentruber J, Korshunov A, Liu XY,
Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA,
Tönjes M, et al: Driver mutations in histone H3.3 and chromatin
remodelling genes in paediatric glioblastoma. Nature. 482:226–231.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DeWitt JC, Mock A and Louis DN: The 2016
WHO classification of central nervous system tumors: What
neurologists need to know. Curr Opin Neurol. 30:643–649. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lo Greco MC, Marano G, La Rocca M,
Acquaviva G, Milazzotto R, Liardo RLE, Basile A, Foti PV, Palmucci
S, David E, et al: Latest advancements in the management of
H3K27M-mutant diffuse intrinsic pontine glioma: A narrative review.
Cancers (Basel). 17:4202025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akdemir EY, Odia Y, Hall MD, Mehta MP and
Kotecha R: An update on H3K27M-altered diffuse midline glioma:
Diagnostic and therapeutic challenges in clinical practice. Pract
Radiat Oncol. 14:443–451. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
China Society for Radiation Oncology, .
Expert consensus of China on radiation therapy for gliomas in 2017.
Chin J Radiat Oncol. 27:123–131. 2018.(In Chinese).
|
|
11
|
Yoon HI, Wee CW, Kim YZ, Seo Y, Im JH, Dho
YS, Kim KH, Hong JB, Park JS, Choi SH, et al: The Korean society
for neuro-oncology (KSNO) guideline for adult diffuse midline
glioma: Version 2021.1. Brain Tumor Res Treat. 9:1–8. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abe H, Natsumeda M, Kanemaru Y, Watanabe
J, Tsukamoto Y, Okada M, Yoshimura J, Oishi M and Fujii Y: MGMT
expression contributes to temozolomide resistance in H3K27M-mutant
diffuse midline gliomas and MGMT silencing to temozolomide
sensitivity in IDH-mutant gliomas. Neurol Med Chir (Tokyo).
58:290–295. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guerra-García P, Marshall LV, Cockle JV,
Ramachandran PV, Saran FH, Jones C and Carceller F: Challenging the
indiscriminate use of temozolomide in pediatric high-grade gliomas:
A review of past, current, and emerging therapies. Pediatr Blood
Cancer. 67:e280112020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mao M, Wu Y and He Q: Recent advances in
targeted drug delivery for the treatment of glioblastoma.
Nanoscale. 16:8689–8707. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oberoi RK, Parrish KE, Sio TT, Mittapalli
RK, Elmquist WF and Sarkaria JN: Strategies to improve delivery of
anticancer drugs across the blood-brain barrier to treat
glioblastoma. Neuro Oncol. 18:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Nunno V, Lombardi G, Simonelli M,
Minniti G, Mastronuzzi A, Di Ruscio V, Corrà M, Padovan M, Maccari
M, Caccese M, et al: The role of adjuvant chemotherapy in patients
with H3K27 altered diffuse midline gliomas: A multicentric
retrospective study. J Neurooncol. 167:145–154. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ali AS, Lombardo J, Niazi MZ, Miller RC,
Alnahhas I, Martinez NL, Andrews DW, Judy KD and Shi W: Concurrent
chemoradiation and tumor treating fields (TTFields, 200 kHz) for
patients with newly diagnosed glioblastoma: Patterns of progression
in a single institution pilot study. J Neurooncol. 160:345–350.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gött H, Kiez S, Dohmen H, Kolodziej M and
Stein M: Tumor treating fields therapy is feasible and safe in a
3-year-old patient with diffuse midline glioma H3K27M-a case
report. Childs Nerv Syst. 38:1791–1796. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ehteda A, Simon S, Franshaw L, Giorgi FM,
Liu J, Joshi S, Rouaen JRC, Pang CNI, Pandher R, Mayoh C, et al:
Dual targeting of the epigenome via FACT complex and histone
deacetylase is a potent treatment strategy for DIPG. Cell Rep.
35:1089942021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hwang EI, Sayour EJ, Flores CT, Grant G,
Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM,
Figg JW, et al: The current landscape of immunotherapy for
pediatric brain tumors. Nat Cancer. 3:11–24. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Estevez-Ordonez D, Gary SE, Atchley TJ,
Maleknia PD, George JA, Laskay NMB, Gross EG, Devulapalli RK and
Johnston JM: Immunotherapy for pediatric brain and spine tumors:
Current state and future directions. Pediatr Neurosurg. 58:313–336.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kline C, Liu SJ, Duriseti S, Banerjee A,
Nicolaides T, Raber S, Gupta N, Haas-Kogan D, Braunstein S and
Mueller S: Reirradiation and PD-1 inhibition with nivolumab for the
treatment of recurrent diffuse intrinsic pontine glioma: A
single-institution experience. J Neurooncol. 140:629–638. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Xu J, Luo N, Qi C and Tao R:
Successful treatment of an adult patient with diffuse midline
glioma employing olaparib combined with bevacizumab. Invest New
Drugs. 39:1432–1435. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Venneti S, Kawakibi AR, Ji S, Waszak SM,
Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, et al:
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline
gliomas is driven by disruption of integrated metabolic and
epigenetic pathways. Cancer Discov. 13:2370–2393. 2023. View Article : Google Scholar : PubMed/NCBI
|
